What is Canid?
Canid operates at the intersection of healthcare AI and enterprise software, providing a specialized platform that transforms the complex, resource-intensive process of vaccine administration into a seamless scan-and-go workflow. By integrating directly with existing electronic health record (EHR) systems, the platform leverages artificial intelligence to reduce the administrative burden on pediatricians, allowing for greater focus on patient care. The company's value proposition centers on economies of scale and workflow optimization, effectively mitigating the time and financial costs associated with immunization compliance and inventory management.
How much funding has Canid raised?
Canid has raised a total of $12.5M across 3 funding rounds:
Angel/Pre-Seed
$1M
Seed
$1.5M
Series A
$10M
Angel/Pre-Seed (2021): $1M, investors not publicly disclosed
Seed (2023): $1.5M led by FJ Labs and Alumni Ventures
Series A (2025): $10M supported by Brooklyn Bridge Ventures, SeedtoB Capital, Telescope Partners, and FJ Labs
Key Investors in Canid
Brooklyn Bridge Ventures
A seed-stage investment firm based in New York that focuses on fostering community-driven growth and supporting innovative startups across diverse sectors including healthcare.
SeedtoB Capital
An investment firm specializing in healthcare AI startups, providing strategic guidance and industry expertise to help companies navigate the critical transition from early-stage development to Series B.
Telescope Partners
A thesis-driven, early-growth investor that partners with entrepreneurs building exceptional enterprise software companies through a high-touch, bespoke investment approach.
What's next for Canid?
With this latest capital injection, Canid is poised to accelerate its market penetration and enhance its platform capabilities. The strategic focus will likely shift toward deepening EHR integrations and expanding the reach of its AI-driven workflow tools to a broader network of healthcare providers. As the company transitions into a more mature enterprise phase, the emphasis will remain on scaling its infrastructure to support high-volume clinical environments, ensuring that the platform remains the definitive solution for pediatric vaccine management in an increasingly digitized healthcare landscape.
See full Canid company page
